Milner Executive Director Cathy Tralau-Stewart attends J.P. Morgan’s 43rd Annual Healthcare Conference
We are delighted that our Executive Director – Dr Cathy Tralau-Stewart – was invited to attend J.P. Morgan’s 43rd Annual Healthcare Conference this week. Cathy was pleased to connect with global industry leaders, emerging fast-growth companies, innovative...
Milner Institute welcomes affiliate network to first B2B Matchmaking Event
Last week, 40 Milner Affiliates joined our inaugural B2B Matchmaking Event here in Cambridge, bringing together a diverse range of start-ups, biotechs and larger services and CRO partners, as well as some of the pharma partners in the Milner Therapeutics Consortium....
Milner joins Cambridge-ARIA collaboration to create new technologies for transforming brain health
We are delighted that the Milner Therapeutics Institute (MTI) has joined a three-year collaboration with the science funding agency ARIA and multiple Cambridge partners, to engineer a new generation of neuro-technologies designed to treat depression, dementia, chronic...
Milner Institute awarded £7m to enable Functional Genomics Screening Laboratory as part of UK wide initiative
We’re delighted to announce that the Medical Research Council (MRC), in collaboration with the Biotechnology and Biological Sciences Research Council (BBSRC), awarded £7m to help establish the MRC-AstraZeneca-University of Cambridge joint Functional Genomics...